Myelodysplastic Syndromes
March 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Myelodysplastic Syndromes abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Myelodysplastic Syndromes. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Myelodysplastic Syndromes. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Myelodysplastic Syndromes every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Authors:Tang Y, Miao M, Han S, Qi J, Wang H, Ruan C, Wu D, Han Y
Institution:Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. Electronic address: wudepei@medmail.com.cn.; Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Collaborative Innovation Center of Hematology of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Suzhou, China; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. Electronic address: hanyue@suda.edu.cn.
Journal:Crit Rev Oncol Hematol. 2019 Jan;133:74-83. doi: 10.1016/j.critrevonc.2018.07.013. Epub 2018 Aug 3.

2:Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant.
Authors:Fozza C
Institution:Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy.
Journal:Crit Rev Oncol Hematol. 2019 Jan;133:112-119. doi: 10.1016/j.critrevonc.2018.11.001. Epub 2018 Nov 16.

3:Long-term safety and efficacy of deferasirox in patients with myelodysplastic syndrome, aplastic anemia and other rare anemia in Taiwan.
Authors:Ko BS, Chang MC, Chiou TJ, Chang TK, Chen YC, Lin SF, Chang CS, Lu YC, Yeh SP, Chen TY, Hwang WS
Institution:a Department of Internal Medicine , National Taiwan University Hospital , Taipei , Taiwan. Taiwan. General Hospital , Taipei , Taiwan. Taiwan. Taiwan. University Hospital , Kaohsiung , Taiwan. Taiwan. Tainan , Taiwan. Taichung , Taiwan.
Journal:Hematology. 2019 Dec;24(1):247-254. doi: 10.1080/16078454.2018.1557860.

4:Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Authors:Taher AT, Origa R, Perrotta S, Kouraklis A, Ruffo GB, Kattamis A, Goh AS, Huang V, Zia A, Herranz RM, Porter JB
Institution:Department of Internal Medicine, Director - Fellowship and Residents Research Program, Faculty of Medicine American University of Beirut Medical Center, Beirut, Lebanon. ataher@aub.edu.lb. Medical School, Patras, Greece. Italy.
Journal:Health Qual Life Outcomes. 2018 Nov 19;16(1):216. doi: 10.1186/s12955-018-1041-5.

5:Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes.
Authors:Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH
Institution:Yale University School of Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, CT, USA. amer.zeidan@yale.edu. at Yale New Haven, New Haven, CT, USA. Philadelphia, PA, USA.
Journal:Ann Hematol. 2019 Feb;98(2):339-350. doi: 10.1007/s00277-018-3539-7. Epub 2018 Nov 9.

6:Autoimmune diseases in myelodysplastic syndrome favors patients survival: A case control study and literature review.
Authors:Seguier J, Gelsi-Boyer V, Ebbo M, Hamidou Z, Charbonnier A, Bernit E, Durand JM, Harle JR, Vey N, Schleinitz N
Institution:Aix-Marseille Univ, APHM, Medecine Interne Hopital de la Timone, Marseille, France. France. France. France. France. France. France. France. France. Electronic address: nicolas.schleinitz@ap-hm.fr.
Journal:Autoimmun Rev. 2019 Jan;18(1):36-42. doi: 10.1016/j.autrev.2018.07.009. Epub 2018 Nov 5.

7:Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Authors:Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K
Institution:Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Center General Hospital, Kobe, Japan. Japan. Japan. Aid Associations Toranomon Hospital, Tokyo, Japan. Isehara, Japan. Medicine, Tokyo, Japan. Japan. Japan. Japan. Hospital, Tokyo, Japan. Medicine, Nagoya, Japan.
Journal:Hematol Oncol. 2019 Feb;37(1):85-95. doi: 10.1002/hon.2566. Epub 2018 Nov 19.

8:Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.
Authors:Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A
Institution:Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. alkali.aref@mayo.edu.
Journal:Ann Hematol. 2019 Feb;98(2):331-337. doi: 10.1007/s00277-018-3509-0. Epub 2018 Oct 18.

9:Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Authors:Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, Elliott K, Robinson J, Abel H, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Brendel K, Saba R, Wartman LD, Christopher MJ, Pusic I, Welch JS, Uy GL, Link DC, DiPersio JF, Westervelt P, Ley TJ, Trinkaus K, Graubert TA, Walter MJ
Institution:From the Department of Pathology and Immunology (E.J.D.), the Department of Medicine, Division of Oncology (M.A.J., C.A.M., N.E., J.S., K.E., J.R., S.E.H., K.B., L.D.W., M.J.C., I.P., J.S.W., G.L.U., D.C.L., J.F.D., P.W., T.J.L., M.J.W.), the McDonnell Genome Institute (G.S.C., C.A.M., H.A., R.S.F., C.C.F., M.O.), the Department of Medicine, Division of Hospital Medicine (R.S.), and Siteman Biostatistics Shared Resource, Siteman Cancer Center (K.T.), Washington University School of Medicine in St. Louis, St. Louis; and Massachusetts General Hospital Cancer Center, Boston (T.A.G.).
Journal:N Engl J Med. 2018 Sep 13;379(11):1028-1041. doi: 10.1056/NEJMoa1804714.

10:Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Authors:Benton CB, Chien KS, Tefferi A, Rodriguez J, Ravandi F, Daver N, Jabbour E, Jain N, Alvarado Y, Kwari M, Pierce S, Maiti A, Hornbaker M, Santos MA, Martinez S, Siguero M, Zblewski D, Al-Kali A, Hogan WJ, Kantarjian H, Pardanani A, Garcia-Manero G
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Hematol Oncol. 2019 Feb;37(1):96-102. doi: 10.1002/hon.2557. Epub 2018 Dec 5.

11:Autoimmune manifestations associated with myelodysplastic syndromes.
Authors:Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A
Institution:Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Cochin, 75014, Paris, France.; Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Assistance Publique - Hopitaux de Paris, Hopital Saint-Antoine, 184, rue du Faubourg Saint-Antoine, 75012, Paris, France. arsene.mekinian@aphp.fr.; UPMC University Paris 06, Paris, France. arsene.mekinian@aphp.fr.; Department of Hematology, Assistance Publique-Hopitaux de Paris, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France.; Sorbonne Universites, UMPC University Paris 06, INSERM U938, Centre de Recherche Saint-Antoine (CRSA), Paris, France. arsene.mekinian@aphp.fr.
Journal:Ann Hematol. 2018 Nov;97(11):2015-2023. doi: 10.1007/s00277-018-3472-9. Epub 2018 Aug 8.

12:Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Authors:Wang H, Li Y, Lv N, Li Y, Wang L, Yu L
Institution:Department of Hematology and BMT Center, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. Road, Beijing, 100853, China. 572013, Hainan Province, China. Road, Beijing, 100853, China. Shenzhen University, 1098 Xueyuan Ave, Shenzhen, 518060, China. Road, Beijing, 100853, China. Road, Beijing, 100853, China.
Journal:Ann Hematol. 2018 Nov;97(11):2025-2038. doi: 10.1007/s00277-018-3464-9. Epub 2018 Aug 6.

13:Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy.
Authors:Schuler E, Zadrozny N, Blum S, Schroeder T, Strupp C, Hildebrandt B, Kundgen A, Gattermann N, Aul C, Kondakci M, Kobbe G, Haas R, Germing U
Institution:Department of Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich Heine-University, Moorenstr. 5, 40225, Dusseldorf, Germany. Esther.Schuler@med.uni-duesseldorf.de.; Department of Oncology, University Hospital, Lausanne, Switzerland.; Institute of Human Genetics and Anthropology, Heinrich Heine-University, Duesseldorf, Germany.; Department of Hematology and Oncology, Johannes Hospital Duisburg, Duisburg, Germany.
Journal:Ann Hematol. 2018 Dec;97(12):2325-2332. doi: 10.1007/s00277-018-3466-7. Epub 2018 Aug 4.

14:Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Authors:Baek DW, Lee YJ, Kim H, Ahn SY, Ahn JS, Shin HJ, Lee WS, Lee SM, Song IC, Lee HS, Park SW, Choi Y, Cho YY, Bae SH, Kim HJ, Sohn SK, Moon JH
Institution:Department of Hematology/Oncology, Kyungpook National University Hospital, 130 Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. South Korea. Hwasun, South Korea. Hwasun, South Korea. Hwasun, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. Dongdeok-ro, Jung-gu, Daegu, 41944, South Korea. jhmoon@knu.ac.kr. jhmoon@knu.ac.kr.
Journal:Ann Hematol. 2018 Dec;97(12):2309-2317. doi: 10.1007/s00277-018-3458-7. Epub 2018 Aug 2.

15:Prognostic impact of elevated pretreatment serum ferritin in patients with high-risk MDS treated with azacitidine.
Authors:Laribi K, Bolle D, Alani M, Ghnaya H, Le Bourdelles S, Besancon A, Farhi J, Denizon N, Baugier de Materre A
Institution:Department of Hematology, Centre Hospitalier Le Mans, Le Mans, France. Electronic address: klaribi@ch-lemans.fr.
Journal:Exp Hematol. 2018 Sep;65:34-37. doi: 10.1016/j.exphem.2018.05.006. Epub 2018 Jun 5.

16:Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes.
Authors:Gayoso J, Balsalobre P, Kwon M, Herrera P, Bermudez A, Sampol A, Jimenez S, Lopez-Corral L, Serrano D, Pinana JL, Pascual MJ, Heras I, Bento L, Varela R, Humala K, Zabalza A, Laiglesia A, Bastos-Oreiro M, Perez-Corral A, Martinez-Laperche C, Buno I, Diez-Martin JL
Institution:Facultad de Medicina Universidad Complutense, HGU Gregorio Maranon, Madrid, Spain. Spain. Spain. Spain. Spain. Spain. Spain. Spain. Spain.
Journal:Eur J Haematol. 2018 Sep;101(3):332-339. doi: 10.1111/ejh.13103. Epub 2018 Aug 3.

17:The genetic and molecular pathogenesis of myelodysplastic syndromes.
Authors:Shallis RM, Ahmad R, Zeidan AM
Institution:Division of Hematology/Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. School of Medicine, New Haven, CT, USA. School of Medicine, New Haven, CT, USA. University, New Haven, CT, USA.
Journal:Eur J Haematol. 2018 Sep;101(3):260-271. doi: 10.1111/ejh.13092. Epub 2018 Jul 12.

For a FREE PREVIEW of the Medifocus Guidebook on Myelodysplastic Syndromes click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Myelodysplastic Syndromes click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Myelodysplastic Syndromes...
at a Special 20% Discount


Medifocus Guidebook on Myelodysplastic Syndromes

Updated: January 4, 2019
189 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Myelodysplastic Syndromes is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

MS83374702

Coupon Expires: May 19, 2019



What Our Customers Are Saying...

"I purchased the MediFocus Guidebook on Myelodysplastic Syndromes to help my father understand the disease that he has. Doctors in France do not communicate very well the various treatment options neither do they tell you about the prognosis with enough clarity and confidence. We live in France and we believe there is no equivalent in Europe to the service you offer. We have read the Guidebook attentively and have learned a great deal about this condition. The wording is simple enough to be understandable even for non-native English speakers. It was money well spent!"
P.M.
Saint Ismier, France


"Your MediFocus Guidebook on Myelodysplastic Syndromes has been a valuable companion in providing wise counsel to a beleaguered soul. Many times I was comforted by knowing that I could have my questions answered correctly and completely by using your Guidebook. I wouldn't be without it for anything. Thank you again and again."
S.M.
Rockville, Maryland


"Your Medifocus Guidebook on Myelodysplastic Syndromes has been extremely valuable to me in understanding the complicated disease that afflicts me. It can be very depressing but to understand it intellectually can be very calming and heartening. Fear of the unknown is most devastating and your Guidebook provides the facts in an understandable way without 'watering-down' the science. Thank you for your outstanding publication."
N.M.
Los Angeles, California



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.